Streetbeat News

Partnerships

COEP

Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK technology. This platform, which can target multiple antigens simultaneously, now extends its potential applications beyond oncology to various autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:02 pm

ROI

RiskOn International, Inc. (NASDAQ:ROI) announced a five-year development agreement with MeetKai, Inc. for the licensing of the askROI.com platform, aiming to revolutionize the AI-driven solutions landscape. The partnership, starting with early access on March 4, 2024, will leverage MeetKai's conversational AI technologies, which have reached over 50 million users, to offer businesses innovative AI solutions. RiskOn has also established a dedicated sales force to support the integration of generative AI into global business operations.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:01 pm

DPZ

During a conference call, a Domino's Pizza executive projected that the company's 2024 U.S. comparable sales will exceed the long-term guidance of 3%, attributing this optimism to significant catalysts from partnerships with Uber and enhancements in their loyalty program.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:54 pm

TRNR

Interactive Strength's shares surged following the announcement of an exclusive worldwide distribution agreement with WOODWAY for the sale and distribution of CLMBR.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:51 pm

AKLI

Akili, Inc. (NASDAQ:AKLI) and its Japanese partner Shionogi & Co. Ltd announced the submission of the digital therapeutic SDT-001, a localized version of Akili's EndeavorRx for pediatric ADHD, for marketing approval in Japan. The submission follows favorable results from a Phase 3 clinical trial demonstrating significant improvements in ADHD symptoms among pediatric patients. No safety concerns were observed. Approval in Japan could expand access to an effective ADHD treatment option in a market with limited pharmaceutical options for pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:49 pm

ABBV

ALVO

TEVA

Teva Pharmaceuticals and Alvotech announced FDA approval for Simlandi, an interchangeable biosimilar to AbbVie's Humira, for various conditions. Simlandi, exclusively commercialized by Teva in the U.S., is the first high-concentration, citrate-free biosimilar to Humira with interchangeability status. This allows pharmacy-level substitution without prescriber consultation. Teva and Alvotech's strategic partnership, initiated in 2020, was recently extended. Additionally, Teva formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing of Austedo. Following the news, TEVA and ALVO stocks saw significant premarket gains.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 1:49 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

AAPL

NVDA

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) inaugurated its first chip plant in Japan, a move aimed at diversifying supply chains amid U.S.-China trade tensions. This expansion is part of TSMC's global strategy, including a $40 billion investment in Arizona. The company, a key supplier to Nvidia and Apple, is responding to geopolitical pressures for local operations. Additionally, Cathie Wood's Ark ETF sold TSMC and Nvidia shares, reallocating investments towards emerging software companies. TSMC's stock has gained 28% YTD, while Nvidia's stock is up 64%.

Portfolio Pulse from Anusuya Lahiri

February 26, 2024 | 1:44 pm

LIXT

LIXTE Biotechnology has entered into an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) for immune oncology. This agreement allows LIXTE to develop and commercialize a specific patented technology in the field of immune oncology, potentially enhancing its product pipeline and positioning in the biotechnology sector.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:34 pm

BOF

BranchOut Food Inc. (NASDAQ:BOF), a food technology company, announced an expansion of its relationship with the nation's largest warehouse club due to exceptional sales of its Pineapple Chips in California. The expansion includes two new orders worth approximately $900,000 for Q3 2024, extending the product's reach to the Northern California Region and seven additional states in the Southeast. This follows a successful product launch in the Bay Area and Southern California regions.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:24 pm